Latest Insider Transactions at Impel Pharmaceuticals Inc (IMPL)
This section provides a real-time view of insider transactions for Impel Pharmaceuticals Inc (IMPL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of IMPEL PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of IMPEL PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 05
2024
|
Timothy S Nelson |
SELL
Other acquisition or disposition
|
Direct |
10,000
-100.0%
|
-
|
|
Dec 19
2023
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
237,289
-9.3%
|
$0
$0.08 P/Share
|
|
Dec 18
2023
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
237,711
-8.52%
|
$0
$0.11 P/Share
|
|
Dec 15
2023
|
Vivo Capital Viii, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
100,000
-3.46%
|
$0
$0.29 P/Share
|
|
Dec 31
2022
|
John Harold Leaman Chief Fin. & Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,627
-34.31%
|
$10,881
$3.75 P/Share
|
|
Dec 31
2022
|
John Harold Leaman Chief Fin. & Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,571
+50.0%
|
-
|
|
Mar 29
2022
|
Stephen B Shrewsbury Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,606
+20.07%
|
$24,606
$1.97 P/Share
|
|
Dec 22
2021
|
John Hoekman Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+13.49%
|
$20,000
$1.64 P/Share
|
|
Nov 19
2021
|
Timothy S Nelson |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$100,000
$10.76 P/Share
|
|
Sep 21
2021
|
Stephen B Shrewsbury Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
73,384
+37.23%
|
$146,768
$2.46 P/Share
|
|
Aug 18
2021
|
Adrian Adams COB, CEO and President |
BUY
Open market or private purchase
|
Direct |
20,000
+21.03%
|
$280,000
$14.87 P/Share
|
|
Apr 27
2021
|
John Hoekman Chief Scientific Officer |
SELL
Other acquisition or disposition
|
Direct |
275
-0.25%
|
-
|
|
Apr 27
2021
|
John Hoekman Chief Scientific Officer |
BUY
Conversion of derivative security
|
Direct |
4,523
+4.0%
|
-
|
|
Apr 27
2021
|
H Stewart Parker Director |
BUY
Conversion of derivative security
|
Direct |
20,151
+30.63%
|
$261,963
$13.5 P/Share
|
|
Apr 27
2021
|
H Stewart Parker Director |
SELL
Other acquisition or disposition
|
Direct |
2,124
-6.35%
|
-
|
|
Apr 27
2021
|
Ven Bio Global Strategic Fund Ii L.P. |
BUY
Open market or private purchase
|
Direct |
450,000
+14.02%
|
$6,750,000
$15.0 P/Share
|
|
Apr 27
2021
|
Ven Bio Global Strategic Fund Ii L.P. |
BUY
Conversion of derivative security
|
Direct |
2,309,791
+50.0%
|
-
|
|
Apr 27
2021
|
Norwest Venture Partners Xiv, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
825,000
+21.14%
|
$12,375,000
$15.0 P/Share
|
|
Apr 27
2021
|
Norwest Venture Partners Xiv, LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,252,198
+49.44%
|
$13,513,188
$6.75 P/Share
|
|
Apr 27
2021
|
5 Am Ventures V, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
575,000
+50.0%
|
$8,625,000
$15.0 P/Share
|
|
Apr 27
2021
|
5 Am Ventures V, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,309,791
+23.62%
|
$30,027,283
$13.5 P/Share
|
|
Apr 27
2021
|
Vivo Capital Viii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
575,000
+16.59%
|
$8,625,000
$15.0 P/Share
|
|
Apr 27
2021
|
Vivo Capital Viii, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,309,789
+23.62%
|
$30,027,257
$13.5 P/Share
|
|
Apr 27
2021
|
Kkr Iris Investors LLC |
BUY
Open market or private purchase
|
Indirect |
1,100,000
+22.44%
|
$16,500,000
$15.0 P/Share
|
|
Apr 27
2021
|
Kkr Iris Investors LLC |
BUY
Other acquisition or disposition
|
Indirect |
118,712
+4.21%
|
$1,543,256
$13.5 P/Share
|
|
Apr 27
2021
|
Kkr Iris Investors LLC |
BUY
Conversion of derivative security
|
Indirect |
2,583,926
+50.0%
|
-
|